Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled trial

Abstract. Objectives. To evaluate the efficacy of self-administered subcutaneous sumatriptan in the acute treatment of early-morning migraine attacks. Design. A double-blind, randomized, placebo-controlled, cross-over study. Setting. Thirteen neurology centres in France. Subjects. Patients of either sex, 18–65 years old, with two to six attacks of migraine (according to the International Headache Society (IHS) criteria, with or without aura) per month, of which at least two had to be early-morning migraine attacks. One-hundred-and-one patients were included, 96 being evaluable for the first attack and 81 for the cross-over design. Interventions. Two migraine attacks (grade 2/3) were treated with sumatriptan (6 mg) or placebo, with an optional second injection 1–24 h later. Main outcome measures. The primary end-point was headache relief: reduction in headache severity from grade 2/3 (moderate/severe) to grade 1/0 (mild/none) 2 h after treatment. Results. Sumatriptan was superior to placebo for headache relief (32 [78%] vs. 11 [28%] at the first attack; 29 [73%] vs. 8 [20%] at the second; P < 0.001). Because of a significant carry-over effect for some of the secondary end-points, a parallel-group analysis of the first attack was performed, which confirmed a significantly higher efficacy of sumatriptan for all end-points: pain-free rate (22 [46%] vs. 7 [15%]; P = 0.001) and use of a second injection (26 [53%] vs. 38 [81%]; P = 0.004). Sumatriptan was preferred by 74% of patients vs. 17% for placebo, and 9% expressed no preference (P < 0.0001). After complete relief, headache reappeared in 8/23 (35%) patients with sumatriptan and 3/7 (43%) with placebo. Adverse events were significantly more frequent with sumatriptan but they were minor and transient. Conclusion. Subcutaneous sumatriptan auto-injection is an effective and well-tolerated acute treatment of early-morning migraine attacks allowing earlier return to normal activity.     

Golgi study on macular mutant mouse after copper therapy

Summary This study was undertaken to elucidate the clinical and neuropathological effects of copper administration on the macular mutant mouse. Its hemizygote, which is considered to be a model of Menkes kinky hair disease (MKHD), was injected intraperitoneally four times with 10, 20, 20 and 30 g of cupric chloride on days 4, 6, 8 and 10, respectively. The hemizygote's curly whiskers gradually straightened and the frequent tonic seizures and ataxia disappeared after the injections. The body weight also gradually increased. In the cerebral cortex, the dendritic arborization of the pyramidal neurons in both the normal littermate and the treated hemizygote developed with time and reached the maximum around day 60. In the treated hemizygote, however, the arborization of the dendrites was significantly poor in comparison with that in the normal littermate from day 20 to 90. In the cerebellum of the treated hemizygote, the abnormal Purkinje cells with the few somal sprouts, thick stem dendrite and/or poor arborization, which were seen in the non-treated hemizygote, were improved by day 30, while their focal dendritic swellings remained even on day 60. These results indicate that the copper therapy improves not only the clinical manifestations but also the neuropathological changes, especially in the cerebellum.Supported in part by Grant no. 86-05-02 from the National Center of Neurology and Psychiatry of the Ministry of Health and Welfare, Japan     

Prospect for enzyme therapy in glycogenosis II variants: a study on cultured muscle cells

Summary Impairment of skeletal muscle function is the common feature of distinct clinical forms of glycogenosis type II. In the present study, muscle cultures from different patients were used to investigate the cause of clinical heterogeneity and the feasibility of enzyme replacement therapy. The activity of acid -glucosidase appears to be the primary factor in determining the extent of lysosomal glycogen storage in muscle, and thereby the clinical severity of the disease. Neutral -glucosidases do not seem influencial. Correction of the enzymatic defect was achieved in skeletal muscle cultures from patients by administration of a high-uptake form of acid -glucosidase, purified from human urine. The enzyme reaches the lysosomes, including the glycogen storage vacuoles, and the lysosomal glycogen content is reduced to control level. In normal muscle cells 20% of the total cellular glycogen pool is segregated in lysosomal compartments. This percentage is higher than in fibroblasts, which may partly explain why muscles are more prone to store glycogen. The relevance of this study for enzyme therapy is discussed.     

Postoperative radiotherapy and radiotherapy combined with CCNU chemotherapy for treatment of brain gliomas

A prospective, randomized trial evaluates the effects of two postoperative treatment regimens on survival in 198 adult patients with supratentorial gliomas. All patients were irradiated with 6 000 rads after possibly radical removal of tumors. CCNU administration in the dosis of 100 mg/sq m of body surface every 6–8 weeks following surgery proved to have no significant effect on the survival of patients. The median survival time in patients receiving radiation therapy alone was 61±7 weeks, while in those receiving additional chemotherapy was 56±4 weeks. Tumor histological malignancy and patients age were found to be the only important prognostic factors, irrespective of the treatment modality. Address for offprints: T Trojanowski, Department of Neurosurgery, Medical School, Jaczewskiego 8, 20-950 Lublin, Poland     

靶向B细胞治疗系统性红斑狼疮研究进展

系统性红斑狼疮(Systemic lupus erythematosus, SLE)是一种慢性、全身多系统受累的自身免疫性疾病。其病因和发病机制尚未完全明确,有研究表明B细胞过度增殖、活化是SLE发病至关重要的环节,也是造成全身多脏器损害的病理基础。因此B细胞成为SLE治疗的新型靶点,本综述主要围绕B细胞相关靶向治疗进展进行讨论,包括靶向B细胞表面抗原、靶向B细胞因子、共刺激阻断、酪氨酸蛋白激酶抑制剂等方面,重点介绍其已经结束或正在进行的临床试验以及实际上市后的临床应用。     

成人斯蒂尔病1例

成人斯蒂尔病起病原因及发生机制仍不清楚,临床主要表现为发热、关节痛、皮疹,且有白细胞、血清铁蛋白等指标增高,但缺乏针对该病的特定诊断指标,导致临床漏诊、误诊比率较高。通过查阅相关文献,发现本病内镜下报道资料较少。本文就1例成人斯蒂尔病病例及胃镜下表现进行报道,并结合AOSD相关诊断指标、治疗方面的最新进展进行归纳,旨在为临床诊疗本病寻求更精准的选择。     

国外经典慢性病管理模式对我国慢性病管理的启示

随着城镇化加快、生活方式变化及全球人口老龄化,慢性病带来的危害日益严重。慢性病的服务提供是卫生服务系统的难题之一,而慢性病管理模式为其创设了一个新的框架。本文主要介绍慢性病照护模式、慢性病自我管理计划和创新型慢性病照护框架3种国外经典慢性病管理模式,从特点、应用效果、局限性等方面进行比较,发现其核心要素包括多方协同、连续性服务、患者自我管理、循证决策、信息技术支持等。以上经验为我国的慢性病管理工作提供了新思路：建立政府主导、多元协同的管理制度,以家庭医生签约服务为“抓手”提高服务连续性,借力智慧医疗并强化患者赋能等,以期取得更好的慢性病管理效果。     

急性冠脉综合征患者强化抗栓治疗研究进展

急性冠脉综合征（ACS）是冠心病的严重类型,ACS患者不仅病死率较高,还存在缺血事件（如缺血性卒中、心肌梗死）复发风险。血小板聚集及血栓形成是导致ACS的重要原因。为降低缺血事件的发生风险,临床推荐ACS患者接受阿司匹林联合强效P2Y12抑制剂的双联抗血小板治疗12个月。然而在标准双联抗血小板治疗下,ACS患者残余缺血风险（经抗栓治疗后仍残留的缺血事件发生风险）仍旧较高。因此为进一步降低缺血事件发生风险,临床对强化抗栓方案的研究也逐渐增多。本文通过总结强化抗栓治疗方案的作用机制及其最新研究进展,发现延长双联抗血小板治疗时间、三联抗血小板治疗、双通道抑制（抗血小板联合抗凝治疗）等强化抗栓治疗方案可降低缺血事件发生风险,为进一步指导临床个体化抗栓治疗及明确最佳抗栓策略提供了参考。     

老年高血压相关性衰弱的发病机制及运动干预机制的研究进展

随着我国老龄化进程的进一步加剧,衰弱作为常见的老年综合征已成为备受关注的公共卫生问题。高血压与衰弱常共存于老年人,导致出现多种不良健康结局。本文分析了老年高血压相关性衰弱的流行现状及发病机制,包括炎性反应、氧化应激反应、胰岛素抵抗及激素代谢紊乱等,总结了运动干预改善高血压相关性衰弱的可能作用途径,并发现目前关于高血压相关性衰弱的运动作用机制类研究仍然缺乏,而且不同类型的运动干预形式对机体的作用机制也存在一定差异性,未来可以进一步探讨不同的运动干预形式对高血压相关性衰弱的作用靶点及干预效果的不同。     

针灸治疗慢性非特异性腰痛随机对照试验结局指标的现状研究

背景 针灸是治疗慢性非特异性腰痛(CNSLBP)的重要方法。随着研究的发展,大量针灸治疗CNSLBP的随机对照试验(RCT)已经发表,但由于在结局指标选择方面存在一定的问题,严重限制了高质量临床证据的产生。目的 评价针灸治疗CNSLBP RCT选用的结局指标情况,为针灸治疗CNSLBP相关研究提供参考依据。方法 系统检索4个中文数据库(中国知网、维普网、万方数据知识服务平台、中国生物医学文献服务系统)、3个英文数据库(PubMed、Embase、Cochrane Library)2017-01-01至2022-03-15发布的针灸治疗CNSLBP的文献,以及自建库以来至2022-03-15发表的非特异性腰痛(NSLBP)的核心结局指标集(COS)。对纳入的针灸治疗CNSLBP的文献基本特征进行分析,对文献的临床结局指标进行归类,对文献中的结局指标及《中医病证诊断疗效标准》的应用现状进行分析。分析NSLBP研究的COS现状,比较其与现有针灸治疗CNSLBP文献结局指标的异同。结果 本研究纳入的针灸治疗CNSLBP的49篇文献均为RCT,共包含4篇英文文献和45篇中文文献。共包含4 272...